Kalpana P. Padala
Associate Professor
Also affiliated: Nebraska Medical Center (2006–2010); University of Arkansas Medical Center (2018–2026); Veterans Health Administration (2012); Institute for Urban and Regional Research (2016); Central Arkansas Veterans Healthcare System (2012–2026); Geriatric Research Education and Clinical Center (2012–2026); Institut Jacques Monod (2025); University of Nebraska Medical Center (2006–2011); Advanced Research Projects Agency - Energy (2020)
Faculty Researcher
Geriatrics, College of Medicine
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Kalpana P. Padala's research focuses on interventions to improve physical activity and cognitive function in older adults, particularly veterans. She has investigated the feasibility and efficacy of using the Nintendo Wii-Fit system to enhance gait and balance, examining factors that influence exercise adherence in this population. Her current work, supported by an RR&D Merit grant, explores the effects of repetitive transcranial magnetic stimulation (rTMS) on executive function, exercise performance, self-efficacy, and adherence to Wii-Fit programs. The overarching goal is to improve balance components in sedentary older veterans by employing engaging home-based exercise programs.
Clinically, Padala evaluates patients in the multidisciplinary memory clinic at the VA and leads the Geriatric Walking Clinic, which she established in 2013. This clinic has served over 800 veterans and their caregivers, providing a setting for naturalistic observation and intervention. Her scholarly contributions include 84 publications with an h-index of 23 and 1,661 citations. Padala collaborates with researchers at the University of Arkansas for Medical Sciences, the University of Arkansas at Fayetteville, and the University of Arkansas at Little Rock.
Research Overview
I have fifteen years of experience in conducting treatment trials in frail elderly. I have focused on alternate modalities to promote exercise in elderly. To overcome various barriers for exercise, I conducted a series of studies investigating the feasibility and efficacy of Nintendo Wii-Fit on gait, and balance in various settings funded by the Alzheimer’s Association and the Department of Veterans Affairs. Later I focused on exercise adherence and ways to improve the same. My current study funded by the RR&D Merit grant is studying the efficacy and lasting effects of repetitive transcranial magnetic stimulation on executive function, exercise performance, self-efficacy and adherence to an adequately dosed, targeted Wii-Fit. The goal of the project is to improve various components of balance in sedentary older Veterans using engaging exercise programs in their home setting. Clinically, I evaluate patients in the multidisciplinary memory clinic at the VA. I also lead the comprehensive physical activity promotion clinic, The Geriatric Walking Clinic that I started in 2013. Over 800 Veterans and caregivers have participated in the program and the clinic provides us a naturalistic experiment to study the impact of COVID-19 restrictions on exercise adherence and executive function in older Veterans. Anecdotally, I see the impact of these restrictions on my clinic patients on a daily basis. I also see the struggles of older Veterans in transitioning to telehealth.
Metrics
- h-index: 23
- Publications: 84
- Citations: 1,679
Selected Publications
-
Uncovering lipid biomarkers linked to methylphenidate efficacy in treating apathy in Alzheimer’s disease: insights from the ADMET 2 trial (2026)
-
Peripheral biomarkers associated with apathy and predicting response to methylphenidate: Secondary analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET2) study (2026)
-
Post COVID-19 waitlist reduction in a memory disorder clinic (2026)
-
Uncovering Lipid Biomarkers Linked to Methylphenidate Efficacy in Treating Apathy in Alzheimer's Disease: Insights from the ADMET 2 trial (2025)
-
The Pitfalls of Patient-Led AI Use: A Case Study in Clinical Neuropsychology (2025)
-
The Relationship of Neuropsychiatric Symptoms, Cognitive Dysfunction and Functional Decline in Older Adults (2025)
-
Escitalopram for agitation in Alzheimer’s dementia: a randomized controlled phase 3 trial (2025)
-
Refining MoCA Interpretation in An Outpatient Clinic Via Logistic Regression and Base Rate Adjustment: A Pilot Study (2025)
-
Escitalopram for Agitation in Alzheimer’s Dementia (2024)
-
Correlation between changes in apathy and cognition in Alzheimer’s disease associated apathy: analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2) (2024)
-
Correlation between changes in apathy and cognition in Alzheimer’s disease associated apathy: Analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2) (2024)
-
Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2 (2024)
-
Doctor AI? A pilot study examining responses of artificial intelligence to common questions asked by geriatric patients (2024)
-
Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial) (2024)
-
Psychiatrists’ Illustration of Awe in Empathic Listening Assessments: A Pilot Study (2024)
Federal Grants 1
Grants & Funding
As listed on this researcher's institutional profile. Federal awards with verified records are shown above.
- DNA Methylation Markers Associated with Exposure and Adverse Health Outcomes in Veterans Exposed to Airborne Hazards from Open Burn Pits. Department of Defense Principal Investigator
- Long-Term Nicotine Treatment of Mild Cognitive Impairment NIH Co-Investigator
- COVID Impact on Physical Activity in Older Veterans Department of Veterans Affairs Principal Investigator
- Immersive Virtual Reality for Apathy associated with Cognitive Impairment. VA ORD RRD – Diversity Supplement Co-Investigator
- A Randomized, Double-blind, Placebo-controlled Phase 3 Study to assess the Efficacy and Safety of Ad26COVS1 for the Prevention of SARS-CoV-2 mediated COVID-19 in Adults Aged 18 Years and Older Janssen Vaccines & Prevention B.V. Principal Investigator
- Wii-Fit for balance and gait in elderly Veterans South Central VA Health Care Network Research Grants Principal Investigator
- Wii-Fit for improving activity, gait and balance in Alzheimer’s Dementia Alzheimer's Association Principal Investigator
- A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF) Romark Medical Research Institute Principal Investigator
- A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Safety, Tolerability, And Pharmacodynamics Of CVL-871 In Subjects With Dementia-Related Apathy Cerevel Therapeutics, LLC Co-Investigator
- Escitalopram for Agitation in Alzheimer's Disease (S-CitAD) (IRB 274855) NIH/Nat. Inst. on Aging via Johns Hopkins University Co-Investigator
- A rTMS and Virtual Reality Based Cognitive Rehabilitation Program for MCI National Academy of Neuropsychology Co-Investigator
- Transcranial Magnetic Stimulation for Apathy in Mild Cognitive Impairment VA ORD RR&D Merit Co-Investigator
Collaboration Network
Top Collaborators
- A systematic review of loneliness and social isolation scales used in epidemics and pandemics
- Veterans Affairs Health Care Provider Perceptions of Virtual Reality: Brief Exploratory Survey
- Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial
- Stress of Overseas Long-Distance Care During COVID-19: Potential “CALM”ing Strategies
- Celebrating the Greatest Generation during the pandemic
Showing 5 of 11 shared publications
- Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease
- Escitalopram for agitation in Alzheimer’s dementia: a randomized controlled phase 3 trial
- Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial
- Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study
- Escitalopram for Agitation in Alzheimer’s Dementia
Showing 5 of 10 shared publications
- Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease
- Escitalopram for agitation in Alzheimer’s dementia: a randomized controlled phase 3 trial
- Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial
- Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study
- Escitalopram for Agitation in Alzheimer’s Dementia
Showing 5 of 9 shared publications
- Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease
- Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial
- Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study
- Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial)
- Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2
Showing 5 of 8 shared publications
- Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease
- Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial
- Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study
- Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial)
- Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2
Showing 5 of 8 shared publications
- Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease
- Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial
- Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study
- Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial)
- Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2
Showing 5 of 8 shared publications
- Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease
- Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial
- Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study
- Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial)
- Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2
Showing 5 of 8 shared publications
- Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease
- Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial
- Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study
- Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial)
- Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2
Showing 5 of 8 shared publications
- Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease
- Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial
- Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study
- Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial)
- Heterogeneity of response to methylphenidate in apathetic patients in the ADMET 2 Trial
Showing 5 of 7 shared publications
- Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease
- Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial
- Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study
- Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial)
- Heterogeneity of response to methylphenidate in apathetic patients in the ADMET 2 Trial
Showing 5 of 7 shared publications
- Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease
- Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial
- Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial)
- Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2
- Heterogeneity of response to methylphenidate in apathetic patients in the ADMET 2 Trial
Showing 5 of 7 shared publications
- Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease
- Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial
- Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial)
- Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2
- Heterogeneity of response to methylphenidate in apathetic patients in the ADMET 2 Trial
Showing 5 of 6 shared publications
- Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease
- Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial
- Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study
- Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial)
- Heterogeneity of response to methylphenidate in apathetic patients in the ADMET 2 Trial
Showing 5 of 6 shared publications
- Veterans Affairs Health Care Provider Perceptions of Virtual Reality: Brief Exploratory Survey
- Celebrating the Greatest Generation during the pandemic
- The influence of social determinants of health on <scp>post‐discharge</scp> mortality of veterans who received care in a transitional care unit
- A systematic review of loneliness and social isolation scales used in epidemics and pandemics
- Stress of Overseas Long-Distance Care During COVID-19: Potential “CALM”ing Strategies
- Loneliness, social connectedness, and resilience during COVID pandemic among those with and without cognitive impairment
Similar Researchers
Based on overlapping research topics